The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches

Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV reactivation with vaccines and antiviral T cell...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cytotherapy (Oxford, England) Ročník 16; číslo 7; s. 927 - 933
Hlavní autori:	Jain, Natasha A., Lu, Kit, Ito, Sawa, Muranski, Pawel, Hourigan, Christopher S., Haggerty, Janice, Chokshi, Puja D., Ramos, Catalina, Cho, Elena, Cook, Lisa, Childs, Richard, Battiwalla, Minoo, Barrett, A. John
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Inc 01.07.2014
Predmet:	Adolescent Adult Advanced Basic Science Aged antiviral cellular therapy Child CMV reactivation Cost of Illness Cytomegalovirus - genetics Cytomegalovirus - pathogenicity Cytomegalovirus Infections - economics Cytomegalovirus Infections - pathology Cytomegalovirus Infections - virology economic cost Female Hematologic Neoplasms - mortality Hematologic Neoplasms - pathology Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - economics Humans Male Middle Aged Other pre-emptive therapy Risk Factors T-Lymphocytes - immunology T-Lymphocytes - pathology T-Lymphocytes - virology Tissue Donors Transplantation, Homologous - adverse effects Transplantation, Homologous - economics Virus Activation - genetics economic cost CMV reactivation pre-emptive therapy antiviral cellular therapy
ISSN:	1465-3249, 1477-2566, 1477-2566
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV reactivation with vaccines and antiviral T cells may represent an advance over pre-emptive strategies but have yet to be justified in terms of transplantation outcome and cost. We compared outcomes and post-transplantation treatment cost in 44 patients who never required pre-emptive CMV treatment with 90 treated patients undergoing SCT at our institute between 2006 and 2012. Eighty-one subjects received CD34+ selected myeloablative SCT, 12 umbilical cord blood transplants, and 41 T-replete non-myeloablative SCT. One hundred nineteen patients (89%) were at risk for CMV because either the donor or recipient was seropositive. Of these, 90 patients (75.6%) reactivated CMV at a median of 30 (range 8–105) days after transplantation and received antivirals. There was no difference in standard transplantation risk factors between the two groups. In multivariate modeling, CMV reactivation >250 copies/mL (odds ratio = 3, P < 0.048), total duration of inpatient IV antiviral therapy (odds ratio = 1.04, P < 0.001), type of transplantation (T-deplete vs. T-replete; odds ratio = 4.65, P < 0.017) were found to be significantly associated with increased non-relapse mortality. The treated group incurred an additional cost of antiviral medication and longer hospitalization within the first 6 months after SCT of $58,000 to $74,000 per patient. Our findings suggest that to prevent CMV reactivation, treatment should be given within 1 week of SCT. Preventative treatment may improve outcome and have significant cost savings.
AbstractList	Abstract Background aims Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV reactivation with vaccines and antiviral T cells may represent an advance over pre-emptive strategies but have yet to be justified in terms of transplantation outcome and cost. Methods We compared outcomes and post-transplantation treatment cost in 44 patients who never required pre-emptive CMV treatment with 90 treated patients undergoing SCT at our institute between 2006 and 2012. Eighty-one subjects received CD34+ selected myeloablative SCT, 12 umbilical cord blood transplants, and 41 T-replete non-myeloablative SCT. One hundred nineteen patients (89%) were at risk for CMV because either the donor or recipient was seropositive. Of these, 90 patients (75.6%) reactivated CMV at a median of 30 (range 8–105) days after transplantation and received antivirals. Results There was no difference in standard transplantation risk factors between the two groups. In multivariate modeling, CMV reactivation >250 copies/mL (odds ratio = 3, P < 0.048), total duration of inpatient IV antiviral therapy (odds ratio = 1.04, P < 0.001), type of transplantation (T-deplete vs. T-replete; odds ratio = 4.65, P < 0.017) were found to be significantly associated with increased non-relapse mortality. The treated group incurred an additional cost of antiviral medication and longer hospitalization within the first 6 months after SCT of $58,000 to $74,000 per patient. Conclusions Our findings suggest that to prevent CMV reactivation, treatment should be given within 1 week of SCT. Preventative treatment may improve outcome and have significant cost savings. Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV reactivation with vaccines and antiviral T cells may represent an advance over pre-emptive strategies but have yet to be justified in terms of transplantation outcome and cost. We compared outcomes and post-transplantation treatment cost in 44 patients who never required pre-emptive CMV treatment with 90 treated patients undergoing SCT at our institute between 2006 and 2012. Eighty-one subjects received CD34+ selected myeloablative SCT, 12 umbilical cord blood transplants, and 41 T-replete non-myeloablative SCT. One hundred nineteen patients (89%) were at risk for CMV because either the donor or recipient was seropositive. Of these, 90 patients (75.6%) reactivated CMV at a median of 30 (range 8–105) days after transplantation and received antivirals. There was no difference in standard transplantation risk factors between the two groups. In multivariate modeling, CMV reactivation >250 copies/mL (odds ratio = 3, P < 0.048), total duration of inpatient IV antiviral therapy (odds ratio = 1.04, P < 0.001), type of transplantation (T-deplete vs. T-replete; odds ratio = 4.65, P < 0.017) were found to be significantly associated with increased non-relapse mortality. The treated group incurred an additional cost of antiviral medication and longer hospitalization within the first 6 months after SCT of $58,000 to $74,000 per patient. Our findings suggest that to prevent CMV reactivation, treatment should be given within 1 week of SCT. Preventative treatment may improve outcome and have significant cost savings. Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV reactivation with vaccines and antiviral T cells may represent an advance over pre-emptive strategies but have yet to be justified in terms of transplantation outcome and cost.BACKGROUND AIMSAlthough cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for viral reactivation has toxicity and carries a financial burden. New strategies to prevent CMV reactivation with vaccines and antiviral T cells may represent an advance over pre-emptive strategies but have yet to be justified in terms of transplantation outcome and cost.We compared outcomes and post-transplantation treatment cost in 44 patients who never required pre-emptive CMV treatment with 90 treated patients undergoing SCT at our institute between 2006 and 2012. Eighty-one subjects received CD34+ selected myeloablative SCT, 12 umbilical cord blood transplants, and 41 T-replete non-myeloablative SCT. One hundred nineteen patients (89%) were at risk for CMV because either the donor or recipient was seropositive. Of these, 90 patients (75.6%) reactivated CMV at a median of 30 (range 8-105) days after transplantation and received antivirals.METHODSWe compared outcomes and post-transplantation treatment cost in 44 patients who never required pre-emptive CMV treatment with 90 treated patients undergoing SCT at our institute between 2006 and 2012. Eighty-one subjects received CD34+ selected myeloablative SCT, 12 umbilical cord blood transplants, and 41 T-replete non-myeloablative SCT. One hundred nineteen patients (89%) were at risk for CMV because either the donor or recipient was seropositive. Of these, 90 patients (75.6%) reactivated CMV at a median of 30 (range 8-105) days after transplantation and received antivirals.There was no difference in standard transplantation risk factors between the two groups. In multivariate modeling, CMV reactivation >250 copies/mL (odds ratio = 3, P < 0.048), total duration of inpatient IV antiviral therapy (odds ratio = 1.04, P < 0.001), type of transplantation (T-deplete vs. T-replete; odds ratio = 4.65, P < 0.017) were found to be significantly associated with increased non-relapse mortality. The treated group incurred an additional cost of antiviral medication and longer hospitalization within the first 6 months after SCT of $58,000 to $74,000 per patient.RESULTSThere was no difference in standard transplantation risk factors between the two groups. In multivariate modeling, CMV reactivation >250 copies/mL (odds ratio = 3, P < 0.048), total duration of inpatient IV antiviral therapy (odds ratio = 1.04, P < 0.001), type of transplantation (T-deplete vs. T-replete; odds ratio = 4.65, P < 0.017) were found to be significantly associated with increased non-relapse mortality. The treated group incurred an additional cost of antiviral medication and longer hospitalization within the first 6 months after SCT of $58,000 to $74,000 per patient.Our findings suggest that to prevent CMV reactivation, treatment should be given within 1 week of SCT. Preventative treatment may improve outcome and have significant cost savings.CONCLUSIONSOur findings suggest that to prevent CMV reactivation, treatment should be given within 1 week of SCT. Preventative treatment may improve outcome and have significant cost savings.
Author	Muranski, Pawel Hourigan, Christopher S. Ramos, Catalina Haggerty, Janice Lu, Kit Cho, Elena Battiwalla, Minoo Childs, Richard Ito, Sawa Jain, Natasha A. Barrett, A. John Cook, Lisa Chokshi, Puja D.
Author_xml	– sequence: 1 givenname: Natasha A. surname: Jain fullname: Jain, Natasha A. – sequence: 2 givenname: Kit surname: Lu fullname: Lu, Kit – sequence: 3 givenname: Sawa surname: Ito fullname: Ito, Sawa – sequence: 4 givenname: Pawel surname: Muranski fullname: Muranski, Pawel – sequence: 5 givenname: Christopher S. surname: Hourigan fullname: Hourigan, Christopher S. – sequence: 6 givenname: Janice surname: Haggerty fullname: Haggerty, Janice – sequence: 7 givenname: Puja D. surname: Chokshi fullname: Chokshi, Puja D. – sequence: 8 givenname: Catalina surname: Ramos fullname: Ramos, Catalina – sequence: 9 givenname: Elena surname: Cho fullname: Cho, Elena – sequence: 10 givenname: Lisa surname: Cook fullname: Cook, Lisa – sequence: 11 givenname: Richard surname: Childs fullname: Childs, Richard – sequence: 12 givenname: Minoo surname: Battiwalla fullname: Battiwalla, Minoo email: minoo.battiwalla@nih.gov – sequence: 13 givenname: A. John surname: Barrett fullname: Barrett, A. John
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/24831837$$D View this record in MEDLINE/PubMed
BookMark	eNqFUktuFDEQbaEg8oELsEBesunBdrs_gxBSFPGTIrEgrK1qd_XEjdtubPdIs-MQHIBbsM9RchLcmYRFJII3dqneq1d-VcfZgXUWs-w5oytGWfVqWA1qF1ecMrGifEUZfZQdMVHXOS-r6mB5V2VecLE-zI5DGCjltGnKJ9khF03BmqI-yn5fXCJRRlutwBCwHem1Bat0itrZd2iJ68nkMcdxinqLZAQLGxzRxpS5-pU6cCNuwLit9nMgnQ4IAQn0ET0BY9wGLWpFQsSRKDSGRA82TAZshKidvf7xU4-TSQ0sUSC984vgFm_ySTF6hHgjCNPkHahLDE-zxz2YgM9u75Ps6_t3F2cf8_PPHz6dnZ7nqljzmCNr-rrsm34NFa9Ey7CslVKtYljV2BddWSAIkWAKoCkLtQbarDmtuGC0a6E4yV7u6ybh7zOGKEcdll-ARTcHycpCiKpJJ0Ff3ELndsROTl6P4HfyzuwE4HuA8i4Ej_1fCKNymagc5DJRuUxUUi7TRBOpuUdSeu9bslGbh6lv9lRMBm01ehmURquw0x5VlJ3TD9Pf3qPf7ck33GEY3Oxtsl4yGRJBflm2bVk2JigtqVgKvP53gf-p_wFL0ezT
CitedBy_id	crossref_primary_10_1080_14760584_2018_1526085 crossref_primary_10_1016_j_retram_2018_08_004 crossref_primary_10_1182_blood_2020010028 crossref_primary_10_1002_mco2_70206 crossref_primary_10_7889_tct_25_001 crossref_primary_10_1016_j_beha_2018_09_011 crossref_primary_10_1016_j_bbmt_2018_05_017 crossref_primary_10_1111_imj_14462 crossref_primary_10_2217_fmb_2017_0095 crossref_primary_10_1111_tid_13222 crossref_primary_10_1111_voxs_12130 crossref_primary_10_1016_j_jtct_2024_05_021 crossref_primary_10_1111_tid_13947 crossref_primary_10_1097_MOH_0000000000000090 crossref_primary_10_1016_j_bbmt_2018_11_028 crossref_primary_10_1038_s41409_021_01394_8 crossref_primary_10_1016_j_bbmt_2019_11_005 crossref_primary_10_3389_fcimb_2022_865170 crossref_primary_10_1172_JCI174184 crossref_primary_10_1016_j_jaci_2017_07_008 crossref_primary_10_1111_tid_13233 crossref_primary_10_3390_ijms25020812 crossref_primary_10_1080_03007995_2019_1649379 crossref_primary_10_1182_bloodadvances_2023011033 crossref_primary_10_1097_MOH_0000000000000461 crossref_primary_10_1097_MPH_0000000000000730 crossref_primary_10_1002_cpdd_792 crossref_primary_10_1182_blood_2018_10_878918 crossref_primary_10_1093_ofid_ofac687 crossref_primary_10_1200_JCO_2017_73_0655 crossref_primary_10_1002_jmv_26462 crossref_primary_10_1080_03007995_2019_1664826 crossref_primary_10_1016_j_jtct_2022_06_016 crossref_primary_10_1080_03007995_2019_1664827 crossref_primary_10_1002_jmv_25574 crossref_primary_10_1002_jmv_25895 crossref_primary_10_1016_j_bbmt_2018_10_011 crossref_primary_10_1111_tid_14216 crossref_primary_10_1080_14712598_2016_1229773 crossref_primary_10_4103_ijmm_IJMM_17_269 crossref_primary_10_1016_j_jcyt_2016_05_005 crossref_primary_10_1186_s12967_022_03803_y crossref_primary_10_1016_j_jcyt_2017_07_012 crossref_primary_10_1038_bmt_2016_89 crossref_primary_10_1016_j_bbmt_2020_06_025 crossref_primary_10_1186_s12879_017_2854_2 crossref_primary_10_1111_tid_12961 crossref_primary_10_1016_j_bbmt_2016_12_635 crossref_primary_10_1016_j_cellimm_2023_104795 crossref_primary_10_1038_s41409_017_0035_y crossref_primary_10_1097_QCO_0000000000000517 crossref_primary_10_21320_2500_2139_2022_15_3_289_297
Cites_doi	10.1016/j.bbmt.2007.03.009 10.1086/338624 10.1182/blood-2012-08-448977 10.1182/blood-2003-10-3616 10.1182/asheducation-2013.1.342 10.1016/j.jcyt.2013.11.010 10.1016/j.bbmt.2003.08.011 10.1086/342332 10.1046/j.1365-2141.2001.02519.x 10.1093/infdis/jis107 10.1046/j.1365-2141.2003.04671.x 10.1086/339329 10.1111/j.1600-0609.2007.01006.x 10.1182/blood.V86.7.2815.2815 10.1038/nm1475 10.1182/blood.V88.10.4063.bloodjournal88104063 10.1093/clinids/14.4.831 10.1016/j.bbmt.2006.12.454 10.1126/science.1352912 10.1016/S0140-6736(03)14634-X 10.1016/j.bbmt.2012.05.015 10.1038/sj.bmt.1702450 10.1182/blood.V97.4.867 10.1182/blood-2002-10-3263 10.1084/jem.20040613 10.1182/blood-2012-05-426783 10.1086/520538 10.1016/j.bbmt.2007.02.004 10.1038/mt.2013.151 10.1182/blood.V93.5.1781 10.1182/blood-2013-02-486324 10.1182/blood-2013-02-487074 10.1093/cid/ciq042 10.1038/mt.2012.130 10.1016/j.bcmd.2007.07.003 10.1182/blood-2010-03-273508 10.1056/NEJM199510193331603 10.1182/blood-2005-10-006536 10.1038/sj.bmt.1704216 10.1016/j.bbmt.2009.01.011 10.1038/bmt.2013.49 10.1016/S1473-3099(11)70344-9 10.1182/blood.V99.11.3916 10.1182/blood-2010-08-304121 10.1182/blood.V90.6.2502 10.1038/sj.bmt.1702226
ContentType	Journal Article
Copyright	2014 Published by Elsevier Inc.
Copyright_xml	– notice: 2014 – notice: Published by Elsevier Inc.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.jcyt.2014.02.010
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	1477-2566
EndPage	933
ExternalDocumentID	24831837 10_1016_j_jcyt_2014_02_010 S1465324914005040 1_s2_0_S1465324914005040
Genre	Journal Article Research Support, N.I.H., Intramural
GrantInformation_xml	– fundername: Intramural NIH HHS grantid: Z99 HL999999
GroupedDBID	--- --M .1- .FO .~1 1P~ 1~. 29F 36B 4.4 457 4G. 53G 5GY 5VS 7-5 8P~ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AATTM AAXKI AAXUO AAYWO ABDBF ABGSF ABJNI ABMAC ABMZM ABUDA ABXDB ACDAQ ACGEJ ACGFS ACIEU ACLOT ACRLP ACUHS ACVFH ADBBV ADCNI ADCVX ADEZE ADXPE AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFKVX AFPUW AFRHN AFTJW AFXIZ AGEKW AGHFR AGRDE AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AJWEG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AWYRJ AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DU5 EAP EBC EBS EFJIC EFKBS EFLBG EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA H13 HVGLF HZ~ KOM LUGTX M44 MO0 O-L O9. OAUVE OK~ P-8 P-9 P2P PC. Q38 R2- ROL SDF SPCBC SSH SSI SSU SSZ SV3 T5K TDBHL TFW Z5R ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c392t-e18f75f8f9a6264b1e57cccbc1e67ef3d53ea44e18caa853c9a0892062410dba3
ISICitedReferencesCount	58
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000337655500007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1465-3249 1477-2566
IngestDate	Sun Sep 28 00:14:44 EDT 2025 Mon Jul 21 06:05:49 EDT 2025 Sat Nov 29 07:01:42 EST 2025 Tue Nov 18 22:00:23 EST 2025 Mon Mar 31 10:57:52 EDT 2025 Sun Feb 23 10:18:44 EST 2025 Tue Oct 14 19:33:50 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	economic cost CMV reactivation pre-emptive therapy antiviral cellular therapy
Language	English
License	Published by Elsevier Inc.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c392t-e18f75f8f9a6264b1e57cccbc1e67ef3d53ea44e18caa853c9a0892062410dba3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	24831837
PQID	1534468888
PQPubID	23479
PageCount	7
ParticipantIDs	proquest_miscellaneous_1534468888 pubmed_primary_24831837 crossref_primary_10_1016_j_jcyt_2014_02_010 crossref_citationtrail_10_1016_j_jcyt_2014_02_010 elsevier_sciencedirect_doi_10_1016_j_jcyt_2014_02_010 elsevier_clinicalkeyesjournals_1_s2_0_S1465324914005040 elsevier_clinicalkey_doi_10_1016_j_jcyt_2014_02_010
PublicationCentury	2000
PublicationDate	2014-07-01
PublicationDateYYYYMMDD	2014-07-01
PublicationDate_xml	– month: 07 year: 2014 text: 2014-07-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Cytotherapy (Oxford, England)
PublicationTitleAlternate	Cytotherapy
PublicationYear	2014
Publisher	Elsevier Inc
Publisher_xml	– name: Elsevier Inc
References	Ljungman, Brand, Einsele, Frassoni, Niederwieser, Cordonnier (bib12) 2003; 102 Blyth, Clancy, Simms, Ma, Burgess, Deo (bib45) 2013; 121 Battiwalla, Wu, Bajwa, Radovic, Almyroudis, Segal (bib16) 2007; 13 Boeckh, Gooley, Myerson, Cunningham, Schoch, Bowden (bib4) 1996; 88 Riddell, Watanabe, Goodrich, Li, Agha, Greenberg (bib18) 1992; 257 Ljungman, Engelhard, Link, Biron, Brandt, Brunet (bib10) 1992; 14 Grigoleit, Kapp, Hebart, Fick, Beck, Jahn (bib50) 2007; 196 Micklethwaite, Hansen, Foster, Snape, Antonenas, Sartor (bib20) 2007; 13 Ljungman, Griffiths, Paya (bib29) 2002; 34 Junghanss, Storb, Maris, Carter, Sandmaier, Maloney (bib11) 2003; 123 Green, Leisenring, Stachel, Pergam, Sandmaier, Wald (bib25) 2012; 18 Green, Leisenring, Xie, Walter, Mielcarek, Sandmaier (bib39) 2013; 122 Walter, Greenberg, Gilbert, Finch, Watanabe, Thomas (bib19) 1995; 333 Boeckh, Bowden, Gooley, Myerson, Corey (bib8) 1999; 93 Griffiths, Whitley, Snydman, Singh, Boeckh (bib5) 2008; 15 Matsumura, Narimatsu, Kami, Yuji, Kusumi, Hori (bib26) 2007; 13 Mackinnon, Thomson, Verfuerth, Peggs, Lowdell (bib40) 2008; 40 Schleiss (bib49) 2009; 15 Majhail, Mothukuri, Brunstein, Weisdorf (bib34) 2009; 15 Heslop, Leen (bib42) 2013; 2013 Craddock, Szydlo, Dazzi, Olavarria, Cwynarski, Yong (bib13) 2001; 112 Bacigalupo, Bregante, Tedone, Isaza, Van Lint, Moro (bib6) 1996; 18 Meijer, Dekker, Rozenberg-Arska, Weersink, Verdonck (bib14) 2002; 35 Elmaagacli, Steckel, Koldehoff, Hegerfeldt, Trenschel, Ditschkowski (bib38) 2011; 118 Gerdemann, Katari, Papadopoulou, Keirnan, Craddock, Liu (bib43) 2013; 21 Peggs, Thomson, Samuel, Dyer, Armoogum, Chakraverty (bib41) 2011; 52 Gratama, Boeckh, Nakamura, Cornelissen, Brooimans, Zaia (bib35) 2010; 116 Ito, Pophali, Co, Koklanaris, Superata, Fahle (bib37) 2013; 48 Nichols, Corey, Gooley, Drew, Miner, Huang (bib1) 2001; 97 Nichols, Corey, Gooley, Davis, Boeckh (bib2) 2002; 185 Nakamura, Battiwalla, Solomon, Follmann, Chakrabarti, Cortez (bib17) 2004; 10 La Rosa, Longmate, Lacey, Kaltcheva, Sharan, Marsano (bib28) 2012; 205 Gerdemann, Keirnan, Katari, Yanagisawa, Christin, Huye (bib44) 2012; 20 Bregante, Bertilson, Tedone, Van Lint, Trespi, Mordini (bib7) 2000; 26 Leen, Bollard, Mendizabal, Shpall, Szabolcs, Antin (bib47) 2013; 121 Takami, Mochizuki, Asakura, Yamazaki, Okumura, Nakao (bib30) 2005; 90 Cobbold, Khan, Pourgheysari, Tauro, McDonald, Osman (bib21) 2005; 202 Kharfan-Dabaja, Boeckh, Wilck, Langston, Chu, Wloch (bib48) 2012; 12 Leen, Myers, Sili, Huls, Weiss, Leung (bib22) 2006; 12 Saglio, Hanley, Bollard (bib27) 2014; 16 Meij, Jedema, Zandvliet, van der Heiden, van de Meent, van Egmond (bib46) 2012; 35 Park, Marti, Kurtzberg, Szabolcs (bib23) 2006; 108 Boeckh, Nichols (bib3) 2004; 103 Salzberger, Bowden, Hackman, Davis, Boeckh (bib15) 1997; 90 Vij, Khoury, Brown, Goodnough, Devine, Blum (bib32) 2003; 32 Einsele, Hebart, Kauffmann-Schneider, Sinzger, Jahn, Bader (bib36) 2000; 25 Khera, Zeliadt, Lee (bib33) 2012; 120 Einsele, Ehninger, Hebart, Wittkowski, Schuler, Jahn (bib9) 1995; 86 Einsele, Roosnek, Rufer, Sinzger, Riegler, Loffler (bib24) 2002; 99 Tomonari, Takahashi, Ooi, Tsukada, Konuma, Kato (bib31) 2008; 80 Peggs, Verfuerth, Pizzey, Khan, Guiver, Moss (bib51) 2003; 362 Ljungman (10.1016/j.jcyt.2014.02.010_bib29) 2002; 34 Nichols (10.1016/j.jcyt.2014.02.010_bib1) 2001; 97 Green (10.1016/j.jcyt.2014.02.010_bib25) 2012; 18 Meij (10.1016/j.jcyt.2014.02.010_bib46) 2012; 35 Einsele (10.1016/j.jcyt.2014.02.010_bib9) 1995; 86 Leen (10.1016/j.jcyt.2014.02.010_bib47) 2013; 121 Ito (10.1016/j.jcyt.2014.02.010_bib37) 2013; 48 Majhail (10.1016/j.jcyt.2014.02.010_bib34) 2009; 15 Einsele (10.1016/j.jcyt.2014.02.010_bib36) 2000; 25 Boeckh (10.1016/j.jcyt.2014.02.010_bib8) 1999; 93 Tomonari (10.1016/j.jcyt.2014.02.010_bib31) 2008; 80 Junghanss (10.1016/j.jcyt.2014.02.010_bib11) 2003; 123 Khera (10.1016/j.jcyt.2014.02.010_bib33) 2012; 120 Battiwalla (10.1016/j.jcyt.2014.02.010_bib16) 2007; 13 Vij (10.1016/j.jcyt.2014.02.010_bib32) 2003; 32 Heslop (10.1016/j.jcyt.2014.02.010_bib42) 2013; 2013 Griffiths (10.1016/j.jcyt.2014.02.010_bib5) 2008; 15 Gerdemann (10.1016/j.jcyt.2014.02.010_bib43) 2013; 21 Nichols (10.1016/j.jcyt.2014.02.010_bib2) 2002; 185 Bregante (10.1016/j.jcyt.2014.02.010_bib7) 2000; 26 Green (10.1016/j.jcyt.2014.02.010_bib39) 2013; 122 Nakamura (10.1016/j.jcyt.2014.02.010_bib17) 2004; 10 Bacigalupo (10.1016/j.jcyt.2014.02.010_bib6) 1996; 18 Cobbold (10.1016/j.jcyt.2014.02.010_bib21) 2005; 202 Einsele (10.1016/j.jcyt.2014.02.010_bib24) 2002; 99 Takami (10.1016/j.jcyt.2014.02.010_bib30) 2005; 90 Craddock (10.1016/j.jcyt.2014.02.010_bib13) 2001; 112 Schleiss (10.1016/j.jcyt.2014.02.010_bib49) 2009; 15 Gratama (10.1016/j.jcyt.2014.02.010_bib35) 2010; 116 Peggs (10.1016/j.jcyt.2014.02.010_bib41) 2011; 52 Kharfan-Dabaja (10.1016/j.jcyt.2014.02.010_bib48) 2012; 12 Matsumura (10.1016/j.jcyt.2014.02.010_bib26) 2007; 13 Ljungman (10.1016/j.jcyt.2014.02.010_bib10) 1992; 14 Meijer (10.1016/j.jcyt.2014.02.010_bib14) 2002; 35 Riddell (10.1016/j.jcyt.2014.02.010_bib18) 1992; 257 La Rosa (10.1016/j.jcyt.2014.02.010_bib28) 2012; 205 Elmaagacli (10.1016/j.jcyt.2014.02.010_bib38) 2011; 118 Micklethwaite (10.1016/j.jcyt.2014.02.010_bib20) 2007; 13 Ljungman (10.1016/j.jcyt.2014.02.010_bib12) 2003; 102 Mackinnon (10.1016/j.jcyt.2014.02.010_bib40) 2008; 40 Gerdemann (10.1016/j.jcyt.2014.02.010_bib44) 2012; 20 Peggs (10.1016/j.jcyt.2014.02.010_bib51) 2003; 362 Saglio (10.1016/j.jcyt.2014.02.010_bib27) 2014; 16 Leen (10.1016/j.jcyt.2014.02.010_bib22) 2006; 12 Park (10.1016/j.jcyt.2014.02.010_bib23) 2006; 108 Walter (10.1016/j.jcyt.2014.02.010_bib19) 1995; 333 Blyth (10.1016/j.jcyt.2014.02.010_bib45) 2013; 121 Salzberger (10.1016/j.jcyt.2014.02.010_bib15) 1997; 90 Grigoleit (10.1016/j.jcyt.2014.02.010_bib50) 2007; 196 Boeckh (10.1016/j.jcyt.2014.02.010_bib3) 2004; 103 Boeckh (10.1016/j.jcyt.2014.02.010_bib4) 1996; 88
References_xml	– volume: 35 start-page: 621 year: 2012 end-page: 628 ident: bib46 article-title: Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines publication-title: J Immunother – volume: 202 start-page: 379 year: 2005 end-page: 386 ident: bib21 article-title: Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers publication-title: J Exp Med – volume: 48 start-page: 1313 year: 2013 end-page: 1316 ident: bib37 article-title: CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML publication-title: Bone Marrow Transplant – volume: 80 start-page: 251 year: 2008 end-page: 257 ident: bib31 article-title: Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan publication-title: Eur J Haematol – volume: 26 start-page: 23 year: 2000 end-page: 29 ident: bib7 article-title: Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study publication-title: Bone Marrow Transplant – volume: 21 start-page: 2113 year: 2013 end-page: 2121 ident: bib43 article-title: Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant publication-title: Mol Ther – volume: 122 start-page: 1316 year: 2013 end-page: 1324 ident: bib39 article-title: CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia publication-title: Blood – volume: 12 start-page: 1160 year: 2006 end-page: 1166 ident: bib22 article-title: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals publication-title: Nat Med – volume: 15 start-page: 564 year: 2009 end-page: 573 ident: bib34 article-title: Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications publication-title: Biol Blood Marrow Transplant – volume: 121 start-page: 3745 year: 2013 end-page: 3758 ident: bib45 article-title: Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation publication-title: Blood – volume: 35 start-page: 703 year: 2002 end-page: 712 ident: bib14 article-title: Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors publication-title: Clin Infect Dis – volume: 90 start-page: 1290 year: 2005 end-page: 1292 ident: bib30 article-title: High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant publication-title: Haematologica – volume: 103 start-page: 2003 year: 2004 end-page: 2008 ident: bib3 article-title: The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy publication-title: Blood – volume: 25 start-page: 757 year: 2000 end-page: 763 ident: bib36 article-title: Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection publication-title: Bone Marrow Transplant – volume: 93 start-page: 1781 year: 1999 end-page: 1782 ident: bib8 article-title: Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients publication-title: Blood – volume: 123 start-page: 662 year: 2003 end-page: 670 ident: bib11 article-title: Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation publication-title: Br J Haematol – volume: 362 start-page: 1375 year: 2003 end-page: 1377 ident: bib51 article-title: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines publication-title: Lancet – volume: 32 start-page: 703 year: 2003 end-page: 707 ident: bib32 article-title: Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation publication-title: Bone Marrow Transplant – volume: 257 start-page: 238 year: 1992 end-page: 241 ident: bib18 article-title: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones publication-title: Science – volume: 40 start-page: 63 year: 2008 end-page: 67 ident: bib40 article-title: Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells publication-title: Blood Cells Mol Dis – volume: 88 start-page: 4063 year: 1996 end-page: 4071 ident: bib4 article-title: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study publication-title: Blood – volume: 102 start-page: 4255 year: 2003 end-page: 4260 ident: bib12 article-title: Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis publication-title: Blood – volume: 52 start-page: 49 year: 2011 end-page: 57 ident: bib41 article-title: Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation publication-title: Clin Infect Dis – volume: 2013 start-page: 342 year: 2013 end-page: 347 ident: bib42 article-title: T-cell therapy for viral infections publication-title: Hematology – volume: 15 start-page: 44 year: 2009 end-page: 45 ident: bib49 article-title: Cytomegalovirus vaccines: at last, a major step forward publication-title: Herpes – volume: 90 start-page: 2502 year: 1997 end-page: 2508 ident: bib15 article-title: Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome publication-title: Blood – volume: 121 start-page: 5113 year: 2013 end-page: 5123 ident: bib47 article-title: Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation publication-title: Blood – volume: 14 start-page: 831 year: 1992 end-page: 835 ident: bib10 article-title: Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group publication-title: Clin Infect Dis – volume: 97 start-page: 867 year: 2001 end-page: 874 ident: bib1 article-title: Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes publication-title: Blood – volume: 333 start-page: 1038 year: 1995 end-page: 1044 ident: bib19 article-title: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor publication-title: N Engl J Med – volume: 112 start-page: 228 year: 2001 end-page: 236 ident: bib13 article-title: Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis publication-title: Br J Haematol – volume: 34 start-page: 1094 year: 2002 end-page: 1097 ident: bib29 article-title: Definitions of cytomegalovirus infection and disease in transplant recipients publication-title: Clin Infect Dis – volume: 118 start-page: 1402 year: 2011 end-page: 1412 ident: bib38 article-title: Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients publication-title: Blood – volume: 12 start-page: 290 year: 2012 end-page: 299 ident: bib48 article-title: A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet Infect Dis – volume: 99 start-page: 3916 year: 2002 end-page: 3922 ident: bib24 article-title: Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy publication-title: Blood – volume: 13 start-page: 765 year: 2007 end-page: 770 ident: bib16 article-title: Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis publication-title: Biol Blood Marrow Transplant – volume: 120 start-page: 1545 year: 2012 end-page: 1551 ident: bib33 article-title: Economics of hematopoietic cell transplantation publication-title: Blood – volume: 196 start-page: 699 year: 2007 end-page: 704 ident: bib50 article-title: Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor publication-title: J Infect Dis – volume: 13 start-page: 577 year: 2007 end-page: 583 ident: bib26 article-title: Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients publication-title: Biol Blood Marrow Transplant – volume: 16 start-page: 149 year: 2014 end-page: 159 ident: bib27 article-title: The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care publication-title: Cytotherapy – volume: 116 start-page: 1655 year: 2010 end-page: 1662 ident: bib35 article-title: Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study publication-title: Blood – volume: 20 start-page: 1622 year: 2012 end-page: 1632 ident: bib44 article-title: Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections publication-title: Mol Ther – volume: 108 start-page: 1770 year: 2006 end-page: 1773 ident: bib23 article-title: In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes publication-title: Blood – volume: 205 start-page: 1294 year: 2012 end-page: 1304 ident: bib28 article-title: Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant publication-title: J Infect Dis – volume: 10 start-page: 49 year: 2004 end-page: 57 ident: bib17 article-title: Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure publication-title: Biol Blood Marrow Transplant – volume: 86 start-page: 2815 year: 1995 end-page: 2820 ident: bib9 article-title: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation publication-title: Blood – volume: 185 start-page: 273 year: 2002 end-page: 282 ident: bib2 article-title: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection publication-title: J Infect Dis – volume: 18 start-page: 110 year: 1996 end-page: 114 ident: bib6 article-title: Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct) publication-title: Bone Marrow Transplant – volume: 15 start-page: 4 year: 2008 end-page: 12 ident: bib5 article-title: Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007 publication-title: Herpes – volume: 18 start-page: 1687 year: 2012 end-page: 1699 ident: bib25 article-title: Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation publication-title: Biol Blood Marrow Transplant – volume: 13 start-page: 707 year: 2007 end-page: 714 ident: bib20 article-title: Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation publication-title: Biol Blood Marrow Transplant – volume: 13 start-page: 765 year: 2007 ident: 10.1016/j.jcyt.2014.02.010_bib16 article-title: Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2007.03.009 – volume: 185 start-page: 273 year: 2002 ident: 10.1016/j.jcyt.2014.02.010_bib2 article-title: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection publication-title: J Infect Dis doi: 10.1086/338624 – volume: 121 start-page: 3745 year: 2013 ident: 10.1016/j.jcyt.2014.02.010_bib45 article-title: Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation publication-title: Blood doi: 10.1182/blood-2012-08-448977 – volume: 103 start-page: 2003 year: 2004 ident: 10.1016/j.jcyt.2014.02.010_bib3 article-title: The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy publication-title: Blood doi: 10.1182/blood-2003-10-3616 – volume: 2013 start-page: 342 year: 2013 ident: 10.1016/j.jcyt.2014.02.010_bib42 article-title: T-cell therapy for viral infections publication-title: Hematology doi: 10.1182/asheducation-2013.1.342 – volume: 16 start-page: 149 year: 2014 ident: 10.1016/j.jcyt.2014.02.010_bib27 article-title: The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care publication-title: Cytotherapy doi: 10.1016/j.jcyt.2013.11.010 – volume: 10 start-page: 49 year: 2004 ident: 10.1016/j.jcyt.2014.02.010_bib17 article-title: Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2003.08.011 – volume: 35 start-page: 703 year: 2002 ident: 10.1016/j.jcyt.2014.02.010_bib14 article-title: Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors publication-title: Clin Infect Dis doi: 10.1086/342332 – volume: 112 start-page: 228 year: 2001 ident: 10.1016/j.jcyt.2014.02.010_bib13 article-title: Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2001.02519.x – volume: 15 start-page: 44 year: 2009 ident: 10.1016/j.jcyt.2014.02.010_bib49 article-title: Cytomegalovirus vaccines: at last, a major step forward publication-title: Herpes – volume: 90 start-page: 1290 year: 2005 ident: 10.1016/j.jcyt.2014.02.010_bib30 article-title: High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant publication-title: Haematologica – volume: 205 start-page: 1294 year: 2012 ident: 10.1016/j.jcyt.2014.02.010_bib28 article-title: Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant publication-title: J Infect Dis doi: 10.1093/infdis/jis107 – volume: 123 start-page: 662 year: 2003 ident: 10.1016/j.jcyt.2014.02.010_bib11 article-title: Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2003.04671.x – volume: 34 start-page: 1094 year: 2002 ident: 10.1016/j.jcyt.2014.02.010_bib29 article-title: Definitions of cytomegalovirus infection and disease in transplant recipients publication-title: Clin Infect Dis doi: 10.1086/339329 – volume: 80 start-page: 251 year: 2008 ident: 10.1016/j.jcyt.2014.02.010_bib31 article-title: Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan publication-title: Eur J Haematol doi: 10.1111/j.1600-0609.2007.01006.x – volume: 86 start-page: 2815 year: 1995 ident: 10.1016/j.jcyt.2014.02.010_bib9 article-title: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation publication-title: Blood doi: 10.1182/blood.V86.7.2815.2815 – volume: 12 start-page: 1160 year: 2006 ident: 10.1016/j.jcyt.2014.02.010_bib22 article-title: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals publication-title: Nat Med doi: 10.1038/nm1475 – volume: 88 start-page: 4063 year: 1996 ident: 10.1016/j.jcyt.2014.02.010_bib4 article-title: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study publication-title: Blood doi: 10.1182/blood.V88.10.4063.bloodjournal88104063 – volume: 14 start-page: 831 year: 1992 ident: 10.1016/j.jcyt.2014.02.010_bib10 article-title: Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group publication-title: Clin Infect Dis doi: 10.1093/clinids/14.4.831 – volume: 35 start-page: 621 year: 2012 ident: 10.1016/j.jcyt.2014.02.010_bib46 article-title: Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines publication-title: J Immunother – volume: 13 start-page: 577 year: 2007 ident: 10.1016/j.jcyt.2014.02.010_bib26 article-title: Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2006.12.454 – volume: 257 start-page: 238 year: 1992 ident: 10.1016/j.jcyt.2014.02.010_bib18 article-title: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones publication-title: Science doi: 10.1126/science.1352912 – volume: 362 start-page: 1375 year: 2003 ident: 10.1016/j.jcyt.2014.02.010_bib51 article-title: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines publication-title: Lancet doi: 10.1016/S0140-6736(03)14634-X – volume: 18 start-page: 1687 year: 2012 ident: 10.1016/j.jcyt.2014.02.010_bib25 article-title: Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2012.05.015 – volume: 26 start-page: 23 year: 2000 ident: 10.1016/j.jcyt.2014.02.010_bib7 article-title: Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1702450 – volume: 97 start-page: 867 year: 2001 ident: 10.1016/j.jcyt.2014.02.010_bib1 article-title: Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes publication-title: Blood doi: 10.1182/blood.V97.4.867 – volume: 102 start-page: 4255 year: 2003 ident: 10.1016/j.jcyt.2014.02.010_bib12 article-title: Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis publication-title: Blood doi: 10.1182/blood-2002-10-3263 – volume: 202 start-page: 379 year: 2005 ident: 10.1016/j.jcyt.2014.02.010_bib21 article-title: Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers publication-title: J Exp Med doi: 10.1084/jem.20040613 – volume: 120 start-page: 1545 year: 2012 ident: 10.1016/j.jcyt.2014.02.010_bib33 article-title: Economics of hematopoietic cell transplantation publication-title: Blood doi: 10.1182/blood-2012-05-426783 – volume: 196 start-page: 699 year: 2007 ident: 10.1016/j.jcyt.2014.02.010_bib50 article-title: Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor publication-title: J Infect Dis doi: 10.1086/520538 – volume: 18 start-page: 110 issue: Suppl. 2 year: 1996 ident: 10.1016/j.jcyt.2014.02.010_bib6 article-title: Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct) publication-title: Bone Marrow Transplant – volume: 13 start-page: 707 year: 2007 ident: 10.1016/j.jcyt.2014.02.010_bib20 article-title: Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2007.02.004 – volume: 21 start-page: 2113 year: 2013 ident: 10.1016/j.jcyt.2014.02.010_bib43 article-title: Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant publication-title: Mol Ther doi: 10.1038/mt.2013.151 – volume: 93 start-page: 1781 year: 1999 ident: 10.1016/j.jcyt.2014.02.010_bib8 article-title: Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients publication-title: Blood doi: 10.1182/blood.V93.5.1781 – volume: 121 start-page: 5113 year: 2013 ident: 10.1016/j.jcyt.2014.02.010_bib47 article-title: Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation publication-title: Blood doi: 10.1182/blood-2013-02-486324 – volume: 122 start-page: 1316 year: 2013 ident: 10.1016/j.jcyt.2014.02.010_bib39 article-title: CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia publication-title: Blood doi: 10.1182/blood-2013-02-487074 – volume: 52 start-page: 49 year: 2011 ident: 10.1016/j.jcyt.2014.02.010_bib41 article-title: Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation publication-title: Clin Infect Dis doi: 10.1093/cid/ciq042 – volume: 20 start-page: 1622 year: 2012 ident: 10.1016/j.jcyt.2014.02.010_bib44 article-title: Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections publication-title: Mol Ther doi: 10.1038/mt.2012.130 – volume: 40 start-page: 63 year: 2008 ident: 10.1016/j.jcyt.2014.02.010_bib40 article-title: Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells publication-title: Blood Cells Mol Dis doi: 10.1016/j.bcmd.2007.07.003 – volume: 116 start-page: 1655 year: 2010 ident: 10.1016/j.jcyt.2014.02.010_bib35 article-title: Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study publication-title: Blood doi: 10.1182/blood-2010-03-273508 – volume: 15 start-page: 4 year: 2008 ident: 10.1016/j.jcyt.2014.02.010_bib5 article-title: Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007 publication-title: Herpes – volume: 333 start-page: 1038 year: 1995 ident: 10.1016/j.jcyt.2014.02.010_bib19 article-title: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor publication-title: N Engl J Med doi: 10.1056/NEJM199510193331603 – volume: 108 start-page: 1770 year: 2006 ident: 10.1016/j.jcyt.2014.02.010_bib23 article-title: In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes publication-title: Blood doi: 10.1182/blood-2005-10-006536 – volume: 32 start-page: 703 year: 2003 ident: 10.1016/j.jcyt.2014.02.010_bib32 article-title: Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1704216 – volume: 15 start-page: 564 year: 2009 ident: 10.1016/j.jcyt.2014.02.010_bib34 article-title: Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2009.01.011 – volume: 48 start-page: 1313 year: 2013 ident: 10.1016/j.jcyt.2014.02.010_bib37 article-title: CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2013.49 – volume: 12 start-page: 290 year: 2012 ident: 10.1016/j.jcyt.2014.02.010_bib48 article-title: A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70344-9 – volume: 99 start-page: 3916 year: 2002 ident: 10.1016/j.jcyt.2014.02.010_bib24 article-title: Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy publication-title: Blood doi: 10.1182/blood.V99.11.3916 – volume: 118 start-page: 1402 year: 2011 ident: 10.1016/j.jcyt.2014.02.010_bib38 article-title: Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients publication-title: Blood doi: 10.1182/blood-2010-08-304121 – volume: 90 start-page: 2502 year: 1997 ident: 10.1016/j.jcyt.2014.02.010_bib15 article-title: Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome publication-title: Blood doi: 10.1182/blood.V90.6.2502 – volume: 25 start-page: 757 year: 2000 ident: 10.1016/j.jcyt.2014.02.010_bib36 article-title: Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1702226
SSID	ssj0020885
Score	2.3012462
Snippet	Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by pre-emptive medication for... Abstract Background aims Although cytomegalovirus (CMV) infection after allogeneic stem cell transplantation (SCT) is rarely fatal, the management of CMV by...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	927
SubjectTerms	Adolescent Adult Advanced Basic Science Aged antiviral cellular therapy Child CMV reactivation Cost of Illness Cytomegalovirus - genetics Cytomegalovirus - pathogenicity Cytomegalovirus Infections - economics Cytomegalovirus Infections - pathology Cytomegalovirus Infections - virology economic cost Female Hematologic Neoplasms - mortality Hematologic Neoplasms - pathology Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - economics Humans Male Middle Aged Other pre-emptive therapy Risk Factors T-Lymphocytes - immunology T-Lymphocytes - pathology T-Lymphocytes - virology Tissue Donors Transplantation, Homologous - adverse effects Transplantation, Homologous - economics Virus Activation - genetics
Title	The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1465324914005040 https://www.clinicalkey.es/playcontent/1-s2.0-S1465324914005040 https://dx.doi.org/10.1016/j.jcyt.2014.02.010 https://www.ncbi.nlm.nih.gov/pubmed/24831837 https://www.proquest.com/docview/1534468888
Volume	16
WOSCitedRecordID	wos000337655500007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1477-2566 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020885 issn: 1465-3249 databaseCode: AIEXJ dateStart: 19990101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVAWR databaseName: Taylor & Francis Journals customDbUrl: eissn: 1477-2566 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020885 issn: 1465-3249 databaseCode: TFW dateStart: 19990101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbtswECUSp4tuiv6TfgIWaLJxVOhDmdIyCFI0QRAYSAp4J4wkCrVhy4JlJ_FteoleoKfocTr8iBLSJm0X9UIwRFG0Pc9DcvTmDSHvAQrgeZ47EAA4TPjMSXkxcOJgkIoANwyQKRHXM35-Ho1G8XBj40eTC3M15WUZ3dzE1X81NZ5DY8vU2X8wt70pnsD3aHQ8otnx-NeGt_mOMixeWFGNVOUsKJLzQjhiVine0MwyYLBl78jfO3Sz9XI-Ezh5zK_Gi1XdPMYxFcXls3ocXoyzvpSB7svgv6w1UdbVFHQqU-mMu1R1yWWstFiUFhrv8NuNqLnhMjaiCfgBdGqYYiPotEblt3XRkU4A4xS0DMI5LKH-Am1w9mylvNjYEntOVMmo_gVcQwdn0JTuHsK1yR8wURCPWcYsTmLaczMuJSd0CRfr2gcdCPOOn461IMEv84cOZUw-TPB3lrw_pgRdNfG2g51qpsDjs0i6RN7OpZbh2DRtki2fh3HUI1uHJ8ejUxsMQO8emiQuzTe8PaSUqTY3uWvNdNeeSK2NLh-TR2ZTQw81GJ-QDVE-JftDrYq-PqCXbZJffUD36bDVS18_I9-wmTaIpWhcahFLNWLpvKAdxNIWsdjy_esttFKDVqrQSlu0UolWKtFK70MrRazRLlqpRStt0fqcfP54fHn0yTHVRJwM9wBLR3hRwcMiKmLATTxLPRHyLMvSzBMDLoogDwMBjOFlGQAuYrMY3Cj23QGucd08heAF6ZXzUmwTGrpu7hcBcyFKWeEVcRqkIkojHkMuA047xGvslWRGal9WfJkmDadykkhzJ9LciesnaO4d0rd9Ki00c-_VQQODpDEQTvoJ4vjeXvx3vURt3FedeEmNVyYXnpRd9FnsMSkQxbBnaHuapblecv9xxHcNRhOct6SFoRTzFY4UBowNInztkJcavPZ7N7h_dWfLa_Kw9QJvSG-5WIm35EF2tRzXi12yyUfRrvnH_QRZEiC9
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+clinical+and+financial+burden+of+pre-emptive+management+of%C2%A0cytomegalovirus+disease+after+allogeneic+stem+cell+transplantation-implications+for+preventative+treatment+approaches&rft.jtitle=Cytotherapy+%28Oxford%2C+England%29&rft.au=Jain%2C+Natasha+A&rft.au=Lu%2C+Kit&rft.au=Ito%2C+Sawa&rft.au=Muranski%2C+Pawel&rft.date=2014-07-01&rft.eissn=1477-2566&rft.volume=16&rft.issue=7&rft.spage=927&rft_id=info:doi/10.1016%2Fj.jcyt.2014.02.010&rft_id=info%3Apmid%2F24831837&rft.externalDocID=24831837
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14653249%2FS1465324914X00071%2Fcov150h.gif